Literature DB >> 18768842

Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes.

Masaru Yamamoto1, Tomomi Kiyota, Shannon M Walsh, Jianuo Liu, Jonathan Kipnis, Tsuneya Ikezu.   

Abstract

Vaccination therapy of AD animal models and patients strongly suggests an active role of brain mononuclear phagocytes in immune-mediated clearance of amyloid-beta peptides (Abeta) in brain. Although Abeta uptake by macrophages can be regulated by pro- and anti-inflammatory cytokines, their effects on macrophage-mediated Abeta degradation are poorly understood. To better understand this mechanism of degradation, we examined whether pro- and anti-inflammatory cytokines affect the degradation of Abeta using primary cultured human monocyte-derived macrophages (MDM) and microglia using pulse-chase analysis of fibrillar and oligomer (125)I-Abeta40 and Abeta42. Initial uptake of fibrillar Abeta40 and Abeta42 was 40% and its degradation was saturated by 120 h in both MDM and microglia, compared with an initial uptake of oligomeric Abeta less than 0.5% and saturation of degradation within 24 h. IFN-gamma increased the intracellular retention of fibrillar Abeta40 and Abeta42 by inhibiting degradation, whereas IL-4, IL-10, and TGF-beta1, but not IL-13 and IL-27, enhanced degradation. Fibrillar Abeta degradation in MDM is sensitive to lysosomal and insulin degrading enzyme inhibitors but insensitive to proteasomal and neprilysin inhibitors. IFN-gamma and TNF-alpha directly reduced the expression of insulin degrading enzyme and chaperone molecules (heat shock protein 70 and heat shock cognate protein 70), which are involved in refolding of aggregated proteins. Coculture of MDM with activated, but not naive T cells, suppressed Abeta degradation in MDM, which was partially blocked by a combination of neutralizing Abs against proinflammatory cytokines. These data suggest that proinflammatory cytokines suppress Abeta degradation in MDM, whereas select anti-inflammatory and regulatory cytokines antagonize these effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768842      PMCID: PMC2603577          DOI: 10.4049/jimmunol.181.6.3877

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Metabolic regulation of brain Abeta by neprilysin.

Authors:  N Iwata; S Tsubuki; Y Takaki; K Shirotani; B Lu; N P Gerard; C Gerard; E Hama; H J Lee; T C Saido
Journal:  Science       Date:  2001-05-25       Impact factor: 47.728

2.  Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition.

Authors:  N Iwata; S Tsubuki; Y Takaki; K Watanabe; M Sekiguchi; E Hosoki; M Kawashima-Morishima; H J Lee; E Hama; Y Sekine-Aizawa; T C Saido
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.

Authors:  T Wyss-Coray; C Lin; F Yan; G Q Yu; M Rohde; L McConlogue; E Masliah; L Mucke
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

4.  Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology.

Authors:  J Apelt; R Schliebs
Journal:  Brain Res       Date:  2001-03-09       Impact factor: 3.252

5.  Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells.

Authors:  H Chung; M I Brazil; T T Soe; F R Maxfield
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

6.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

7.  Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice.

Authors:  W C Benzing; J R Wujek; E K Ward; D Shaffer; K H Ashe; S G Younkin; K R Brunden
Journal:  Neurobiol Aging       Date:  1999 Nov-Dec       Impact factor: 4.673

8.  Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice.

Authors:  Nagat Abbas; Ivan Bednar; Eilhard Mix; Svedberg Marie; David Paterson; Anna Ljungberg; Chris Morris; Bengt Winblad; Agneta Nordberg; Jie Zhu
Journal:  J Neuroimmunol       Date:  2002-05       Impact factor: 3.478

9.  A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells.

Authors:  Amit Awasthi; Yijun Carrier; Jean P S Peron; Estelle Bettelli; Masahito Kamanaka; Richard A Flavell; Vijay K Kuchroo; Mohamed Oukka; Howard L Weiner
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

10.  Kinetic analysis of aggregated amyloid-beta peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice.

Authors:  Masaru Yamamoto; Tomomi Kiyota; Shannon M Walsh; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2006-12-05       Impact factor: 4.147

View more
  45 in total

1.  CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice.

Authors:  Tomomi Kiyota; Satoshi Okuyama; Russell J Swan; Michael T Jacobsen; Howard E Gendelman; Tsuneya Ikezu
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

2.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.

Authors:  Sungho Lee; Nicholas H Varvel; Megan E Konerth; Guixiang Xu; Astrid E Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

3.  The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease.

Authors:  Megan M Varnum; Tomomi Kiyota; Kaitlin L Ingraham; Seiko Ikezu; Tsuneya Ikezu
Journal:  Neurobiol Aging       Date:  2015-08-01       Impact factor: 4.673

Review 4.  Microglial phenotype and adaptation.

Authors:  B J L Eggen; D Raj; U-K Hanisch; H W G M Boddeke
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-25       Impact factor: 4.147

Review 5.  Microglia and inflammation in Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

6.  The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

Authors:  Xiqian Lan; Tomomi Kiyota; Richa Hanamsagar; Yunlong Huang; Scott Andrews; Hui Peng; Jialin C Zheng; Susan Swindells; George A Carlson; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-09       Impact factor: 4.147

Review 7.  Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms.

Authors:  Gohar Mushtaq; Jalaluddin A Khan; Taha A Kumosani; Mohammad A Kamal
Journal:  Saudi J Biol Sci       Date:  2014-05-23       Impact factor: 4.219

8.  CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction.

Authors:  Tomomi Kiyota; Masaru Yamamoto; Huangui Xiong; Mary P Lambert; William L Klein; Howard E Gendelman; Richard M Ransohoff; Tsuneya Ikezu
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

9.  The biochemical aftermath of anti-amyloid immunotherapy.

Authors:  Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Eliezer Masliah; James Ar Nicoll; Marwan N Sabbagh; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Mol Neurodegener       Date:  2010-10-07       Impact factor: 14.195

10.  Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes.

Authors:  Kiyotaka Tokuraku; Meg Marquardt; Tsuneya Ikezu
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.